Table I.
Association between NLR and RDW, and clinicopathological characteristics.
| Characteristics | Cases, n | NLR<2.06, n (%) | NLR≥2.06, n (%) | P-value | RDW<13.45, n (%) | RDW≥13.45, n (%) | P-value |
|---|---|---|---|---|---|---|---|
| Sex | 0.224 | 0.622 | |||||
| Male | 167 | 66 (65.3) | 101 (72.7) | 104 (70.7) | 63 (67.7) | ||
| Female | 73 | 35 (34.7) | 38 (27.3) | 43 (29.3) | 30 (32.3) | ||
| Age, years | 0.676 | 0.022 | |||||
| <60 | 94 | 38 (37.6) | 56 (40.3) | 66 (44.9) | 28 (30.1) | ||
| ≥60 | 146 | 63 (62.4) | 83 (59.7) | 81 (55.1) | 65 (69.9) | ||
| Tumor location | 0.046 | 0.457 | |||||
| Colon | 199 | 78 (77.2) | 121 (87.1) | 124 (84.4) | 75 (80.6) | ||
| Rectum | 41 | 23 (22.8) | 18 (12.9) | 23 (15.6) | 18 (19.4) | ||
| Tumor diameter, cm | <0.001 | 0.442 | |||||
| ≤4 | 95 | 55 (64.0) | 40 (33.9) | 65 (48.5) | 30 (42.9) | ||
| >4 | 109 | 31 (36.0) | 78 (66.1) | 69 (51.5) | 40 (57.1) | ||
| Differentiation | 0.004 | 0.799 | |||||
| Well | 7 | 2 (2.0) | 5 (3.6) | 5 (3.4) | 2 (2.2) | ||
| Moderate | 167 | 82 (81.2) | 85 (61.1) | 103 (70.1) | 64 (68.8) | ||
| Poor | 66 | 17 (16.8) | 49 (35.3) | 39 (26.5) | 27 (29.0) | ||
| Tumor depth | 0.012 | 0.634 | |||||
| T1 | 5 | 5 (5.0) | 0 (0.0) | 4 (2.7) | 1 (1.1) | ||
| T2 | 25 | 7 (6.9) | 18 (12.9) | 13 (8.8) | 12 (12.9) | ||
| T3 | 51 | 26 (25.7) | 25 (18.0) | 31 (21.1) | 20 (21.5) | ||
| T4 | 159 | 63 (62.4) | 96 (69.1) | 99 (67.3) | 60 (64.5) | ||
| Lymph node metastasis | 0.210 | 0.527 | |||||
| N0 | 119 | 44 (43.6) | 75 (54.0) | 77 (52.4) | 42 (45.2) | ||
| N1 | 66 | 29 (28.7) | 37 (26.6) | 39 (26.5) | 27 (29.0) | ||
| N2 | 55 | 28 (27.7) | 27 (19.4) | 31 (21.1) | 24 (25.8) | ||
| Distant metastasis | 0.395 | 0.023 | |||||
| M0 | 219 | 94 (93.1) | 125 (89.9) | 139 (94.6) | 80 (86.0) | ||
| M1 | 21 | 7 (6.9) | 14 (10.1) | 8 (5.4) | 13 (14.0) | ||
| pStage | 0.117 | 0.109 | |||||
| I | 22 | 10 (9.9) | 12 (8.6) | 15 (10.2) | 7 (7.5) | ||
| II | 91 | 31 (30.7) | 60 (43.2) | 60 (40.8) | 31 (33.3) | ||
| III | 106 | 53 (52.5) | 53 (38.1) | 64 (43.5) | 42 (45.2) | ||
| IV | 21 | 7 (6.9) | 14 (10.1) | 8 (5.4) | 13 (14.0) | ||
| CEA, ng/ml | 0.045 | 0.881 | |||||
| ≤5 | 100 | 49 (62.0) | 51 (47.2) | 61 (53.0) | 39 (54.2) | ||
| >5 | 87 | 30 (38.0) | 57 (52.8) | 54 (47.0) | 33 (45.8) | ||
| CA19-9, U/ml | 0.030 | 0.142 | |||||
| ≤39 | 155 | 71 (89.9) | 84 (77.8) | 99 (86.1) | 56 (77.8) | ||
| >39 | 32 | 8 (10.1) | 24 (22.2) | 16 (13.9) | 16 (22.2) |
P<0.05 was considered to indicate a statistically significant difference. Total patient numbers vary as pathological data regarding tumor diameter was only available from 204 patients and only 187 patients were examined for tumor markers, CEA and CA19-9. NLR, neutrophil-to-lymphocyte ratio; RDW, red blood cell distribution width; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9.